MUAMU
VKTX icon

Mitsubishi UFJ Asset Management (UK)’s Viking Therapeutics VKTX Stock Holding History

Mitsubishi UFJ Asset Management (UK)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$325K – 107
2026
Q1 		$325K Buy
10,000
+8,000
+400% +$257K 0.17% 85
2025
Q4 		$70K Hold
2,000
– – 0.03% 83
2025
Q3 		$53K Buy
+2,000
New +$59.7K 0.03% 100

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Mitsubishi UFJ Asset Management (UK)'s VKTX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management (UK) sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 10,000 shares — an estimated $325K sold.

Mitsubishi UFJ Asset Management (UK) first reported a position in VKTX in Q3 2025 and held it in 3 quarters. The position peaked at $325K in Q1 2026. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Mitsubishi UFJ Asset Management (UK) reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management (UK) sold 10,000 Viking Therapeutics shares in Q2 2026, an estimated $325K.
  • Mitsubishi UFJ Asset Management (UK) first reported a position in Viking Therapeutics in Q3 2025 and held it in 3 quarters.
  • Mitsubishi UFJ Asset Management (UK)'s Viking Therapeutics position peaked at $325K in Q1 2026.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management (UK)'s 13F filing for Q2 2026, filed 28 Jul 2026.